Skip to main content

Home/ Cancer/ Group items tagged CRPC

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Matti Narkia

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependen... - 0 views

www.nature.com/...6604904a.html

2009 March study review castration-refractory prostate cancer prostate_cancer PCa CRPC abiraterone CYP17 inhibitor inhibition androgen synthesis androgen_synthesis medicine medline abiraterone_acetate

shared by Matti Narkia on 09 Apr 09 - Cached
  • Matti Narkia on 09 Apr 09
     
    CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Ang JE, Olmos D, de Bono JS. Br J Cancer. 2009 Mar 10;100(5):671-5. Epub 2009 Feb 17. PMID: 19223900 doi:10.1038/sj.bjc.6604904
Matti Narkia

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms... - 0 views

jco.ascopubs.org/...4563

2008 Ocober study research clinical_trial phase_I phase_I_trial humans men prostate cancer prostate_cancer PCa aggressive advanced castration-resistant CRPC abiraterone_acetate abiraterone CYP17 inhibitor medicine medline PSA anticacner anti-cancer

shared by Matti Narkia on 09 Apr 09 - Cached
  • Matti Narkia on 09 Apr 09
     
    Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. J Clin Oncol. 2008 Oct 1;26(28):4563-71. Epub 2008 Jul 21. PMID: 18645193 DOI: 10.1200/JCO.2007.15.9749
1 - 2 of 2
Showing 20▼ items per page